News

The decision to suspend the Symmetry trial was based on the results of an analysis by the independent Data Monitoring Committee (DMC) which identified safety concerns, including an

The acquisition of AMO is expected to enhance and strengthen Abbott’s diverse mix of medical device businesses and give it a leadership position in the eye care market.

Highlights Sales revenues of NOK33.2 million in Q4 (+41%) Profit of NOK-9.4 million in Q4, up from NOK-16.3 million in Q4 2007 Sales revenues of NOK100.9 million in

According to the company, this represents the first FDA clearance for Nimbus – a technology that is so unique and that it was put through FDA’s de novo

Also, in a separate action, the FDA issued a class-wide requirement for all manufacturers of metoclopramide in the US to provide a risk evaluation and mitigation strategy (REMS)

Corporate Update During 2008, we implemented our restructuring plan to significantly reduce the rate at which we use our cash and to focus our efforts on opportunities that

The approval of Apidra SoloSTAR follows the approval and launch of Lantus SoloSTAR (insulin glargine (rDNA origin) injection) in 2007. Apidra SoloSTAR is expected to be available in

The company has initiated the filing process for their protocol in Switzerland with the relevant cantonal ethic committees and Swissmedic, the Swiss counterpart to the US FDA. This

The Data Safety Monitoring Board (DSMB) meets every six months to review unblinded safety data from the toremifene Phase III clinical trials. Nearly 1,600 patients with high grade